The new TS-targeted agent pemetrexed was found to have low activity in the treatment of SCLC (Ceppi et al, 2006; Socinski et al, 2009), possibly as a result of a high level of TS expression in such tumours. The gene discussed is TYMS; the disease is neoplasm.